Home Markets Serine/Threonine Protein Kinase ATR Drug Review 2017

Serine/Threonine Protein Kinase ATR Drug Review 2017

88
SHARE

Serine/Threonine Protein Kinase ATR Pipeline and Therapeutics Development H1 2017 provides comprehensive information on the therapeutics under development for Serine/Threonine Protein Kinase ATR, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Serine/Threonine Protein Kinase ATR pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies Involved in Serine/Threonine Protein Kinase ATR Development are AstraZeneca Plc, Bayer AG, Biokine Therapeutics Ltd, Merck & Co Inc, Merck KGaA, Pfizer Inc, Vertex Pharmaceuticals Inc

Sample copy is available at: https://www.marketinsightsreports.com/reports/062215779/serine-threonine-protein-kinase-atr-ataxia-telangiectasia-and-rad3-related-protein-or-frap-related-protein-1-or-atr-or-ec-2-7-11-1-pipeline-review-h1-2017/inquiry  

Scope of this report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Serine/Threonine Protein Kinase ATR. The pipeline guide reviews pipeline therapeutics for Serine/Threonine Protein Kinase ATR by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Serine/Threonine Protein Kinase ATR therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Serine/Threonine Protein Kinase ATR therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Serine/Threonine Protein Kinase ATR.
  • This research report can: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Serine/Threonine Protein Kinase ATR. Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase ATR pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Browse Full Report at: https://www.marketinsightsreports.com/reports/062215779/serine-threonine-protein-kinase-atr-ataxia-telangiectasia-and-rad3-related-protein-or-frap-related-protein-1-or-atr-or-ec-2-7-11-1-pipeline-review-h1-2017

According to the recently published report ‘SerineThreonine Protein Kinase ATR – Pipeline Review, H1 2017’; Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia and Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia and Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) – Serine/threonine-protein kinase ATR is an enzyme encoded by the ATR gene. It is required for cell cycle arrest and DNA damage repair in response to DNA damage. It has shown to phosphorylate checkpoint kinase CHK1, checkpoint proteins RAD17, and RAD9, as well as tumor suppressor protein BRCA1.

The report ‘SerineThreonine Protein Kinase ATR – Pipeline Review, H1 2017’ outlays comprehensive information on the Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 5 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Colorectal Cancer, Ovarian Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Non-Small Cell Lung Cancer, Solid Tumor, Breast Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Lung Adenocarcinoma, Mantle Cell Lymphoma, Metastatic Breast Cancer, Pancreatic Cancer, Prostate Cancer and Small-Cell Lung Cancer.

LEAVE A REPLY

Please enter your comment!
Please enter your name here